Last reviewed 2026-04-20 · How we verify

nifedipen

Al Hayat National Hospital · Phase 1 active Small molecule Quality 0/100

nifedipen is a Small molecule drug developed by Al Hayat National Hospital. It is currently in Phase 1 development. Also known as: inhibiting acute preterm labor.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	nifedipen
Also known as	inhibiting acute preterm labor
Sponsor	Al Hayat National Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

nifedipen CI brief — competitive landscape report
nifedipen updates RSS · CI watch RSS
Al Hayat National Hospital portfolio CI

Frequently asked questions about nifedipen

What is nifedipen?

nifedipen is a Small molecule drug developed by Al Hayat National Hospital.

Who makes nifedipen?

nifedipen is developed by Al Hayat National Hospital (see full Al Hayat National Hospital pipeline at /company/al-hayat-national-hospital).

Is nifedipen also known as anything else?

nifedipen is also known as inhibiting acute preterm labor.

What development phase is nifedipen in?

nifedipen is in Phase 1.

Manufacturer: Al Hayat National Hospital — full pipeline
Therapeutic area: All drugs in Other
Also known as: inhibiting acute preterm labor

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing